Prenetics Global Limited

NASDAQ:PRE

Medical - Diagnostics & Research

Healthcare
$10.31 +2.19%

+$0.43 today

Market cap
$184.89M
Beta
0.24
P/E (TTM)
-4.9
EPS (TTM)
-$4.18
52W Low $7.18High $23.63

Volume 0.82M

Average 0.22M

Financial health

Prenetics Global Limited financial health

Start with the overall verdict and the rule-based risk checks for PRE, then work through liquidity, debt, balance-sheet quality, and claims on cash.

Financial health snapshot

Resilient

Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.

Cash and investments cover debt Healthy short-term liquidity Moderate leverage

Cash & Investments

$108.37M

Debt Cushion

$107.92M

Current Ratio

5.2x

Interest Coverage

Not available

Risk checks

3 of 9 checks flagged

  • Interest coverage

    -220.3×

    Passes when: Operating income is at least 1.5 times interest expense.

  • Debt repayment from cash flow

    Negative FCF

    Passes when: Free cash flow could repay all debt within 5 years.

  • Share dilution

    +13.7% per year

    Passes when: Diluted share count grows no more than 2% per year.

  • Positive equity

    Positive

    Passes when: Shareholders’ equity is above zero.

  • Short-term liquidity

    5.2×

    Passes when: Current assets are at least 1 times current liabilities.

  • Manageable net debt

    Net cash

    Passes when: Net debt is below 3 times EBITDA.

  • Debt growth versus revenue growth

    -30.8% vs. 91.5%

    Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.

  • Tangible equity base

    0.0%

    Passes when: Goodwill and intangibles are below 50% of equity.

  • Altman Z-score trend

    -2.66 → 4.74

    Passes when: The Z-score is stable or rising, or stays above 2.99.

Financial strength scores

How strong are the fundamentals over time?

Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.

Financial strength scores

Piotroski F-Score and Altman Z-Score from the latest reported financials

Piotroski F-Score

Average

4 / 9

Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.

Altman Z-Score

Safe zone

3.10

Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.

Score history

Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.

Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.

Liquidity

Can it meet short-term obligations?

Check whether cash and current assets cover what falls due within a year without depending on fresh financing.

Cash & Equivalents

$56.02M

Q1 2026

3Y +48.1%1Y +74.3%

Quick Ratio

4.6x

Q1 2026

Current Ratio

5.2x

Q1 2026

Cash Ratio

2.2x

Q1 2026

Working capital

How quickly does cash come back?

Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.

Working capital and cash conversion

Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.

Working capital (Q1 2026)

$106.47M

Current assets − current liabilities

Days sales outstanding

12 d

-55 days vs. prior year

Days inventory outstanding

59 d

-98 days vs. prior year

Days payables outstanding

65 d

-23 days vs. prior year

Cash conversion cycle

6 d

-130 days vs. prior year

Leverage

How much debt risk sits on the balance sheet?

Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.

Total Debt

$457,000.00

Q1 2026

3Y -43.8%1Y -79.3%

Debt/Equity

0.0x

Q1 2026

Debt/Assets

0.0x

Q1 2026

Interest Coverage

—

Q1 2026

Debt service

Can cash flow carry the debt?

Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.

Debt service capacity

Can operating cash flow carry the debt, and how much is due soon?

Net debt

Net cash: $105.58M

Total debt − cash − short-term investments

Net debt / EBITDA

Net cash

Above 3× is elevated

Free cash flow / debt

-7471.1%

Share of debt one year of FCF could repay

Years to repay debt

Negative FCF

Total debt ÷ free cash flow

Operating cash flow / current liabilities

-1.3×

Above 1× funds a year of obligations

Interest coverage

-220.3×

Operating income ÷ interest expense

Debt maturity

No short- or long-term borrowings reported.

Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.

Debt and cash over time

Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.

Balance sheet cushion

How much room is there if conditions weaken?

Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.

Long-Term Investments

$2.34M

Q1 2026

3Y -67.5%1Y -96.5%

Assets

$175.30M

Q1 2026

3Y -4.2%1Y -13.9%

Liabilities

$54.28M

Q1 2026

3Y +4.0%1Y +87.1%

Balance sheet quality

Who funds the assets, and how tangible is the equity?

Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.

Balance sheet quality

Who funds the assets, and how much of the equity is tangible (Q1 2026).

Claims on $175.3M in assets

  • Payables1.1%
  • Deferred revenue1.7%
  • Other liabilities28.2%
  • Equity69.0%

Goodwill + intangibles

$40K

0.0% of total assets

Share of equity

0.0%

Above 50% leaves little tangible backing

Tangible equity

$121.08M

Equity left after writing off goodwill and intangibles

Deferred revenue

$2.95M

Customer prepayments: a liability settled by delivering service, not cash

Shareholder claims

What do shareholders take out of the cash?

Dilution, stock-based pay, dividends, and buybacks all draw on cash flow; check whether free cash flow funds them.

Shareholder claims on cash

Dilution, stock-based pay, and whether free cash flow funds what is returned to shareholders.

Diluted shares, yearly change

+13.7%

Compound annual rate from FY 2020 to FY 2025

Stock-based compensation

$141K

Dividends paid

None

TTM to Q1 2026

Dividend / free cash flow

—

Above 100% means dividends exceed free cash flow

Buybacks

$13.12M

TTM to Q1 2026

Weighted diluted shares outstanding

Competitor health

How does Prenetics Global Limited compare with peers?

Compare leverage, interest coverage, and liquidity ratios with similar companies.

Competitor Health

Peer financial health comparison

CompanyMarket CapD/ED/AssetsND/EBITDAInt. Cov.QuickCurrentCash

Profound Medical Corp.

PROF:NASDAQ

$271.77M0.070.031.82—11.1712.529.83

OraSure Technologies, Inc.

OSUR:NASDAQ

$249.95M0.040.033.27—5.806.585.01

TriSalus Life Sciences, Inc.

TLSI:NASDAQ

$149.93M-1.020.97Net cash—2.542.801.78

Armata Pharmaceuticals, Inc.

ARMP:AMEX

$143.89M-1.323.75Net cash—1.191.190.97

Codexis, Inc.

CDXS:NASDAQ

$127.03M1.450.50Net cash—3.753.822.01

MaxCyte, Inc.

MXCT:NASDAQ

$122.82M0.100.090.05—7.778.301.41

Neuronetics, Inc.

STIM:NASDAQ

$108.04M4.040.64Net cash—1.872.021.12

Insight Molecular Diagnostics Inc.

IMDX:NASDAQ

$70.03M-0.110.140.17—1.231.270.96

Atlantic International Corp.

ATLN:NASDAQ

$68.61M-1.200.34Net cash—0.710.710.00

Sangamo Therapeutics, Inc.

SGMO:NASDAQ

$30.66M-1.880.45Net cash—0.840.840.49

Questions

Financial health questions

Common questions about PRE's balance sheet, answered from the reported figures.

Is PRE's balance sheet healthy?

Prenetics Global Limited (PRE) has a current ratio of 5.15, a quick read on short-term liquidity.

How leveraged is PRE?

Debt to equity is 0.00, which helps judge how much financing risk sits on the balance sheet.